John D. Lapek

John D. Lapek

Auto-generated profile, based on publicly available information

John D. Lapek

Pfizer, Oncology Research & Development, San Diego, California

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KFKevin D. Freeman-Cook
Kevin D. Freeman-Cook
RHRobert L. Hoffman
Robert L. Hoffman
DBDouglas C. Behenna
Douglas C. Behenna
BBBritton Boras
Britton Boras
JCJordan Carelli
Jordan Carelli
SDStephen Dann
Stephen Dann

1 May 2019 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
JLJohn D. Lapek
John D. Lapek
ZJZhenze Jiang
Zhenze Jiang
JWJacob M. Wozniak
Jacob M. Wozniak
EAElena Arutyunova
Elena Arutyunova
SWSteven C Wang
Steven C Wang
AOAnthony ODonoghue
Anthony ODonoghue
Proteolysis is an integral component of life and has been implicated in many disease processes. To improve our understanding of peptidase function, it is imperative to develop tools to uncover substrate specificity and cleavage efficiency. Here, we combine the quantitative power of tandem mass tags (TMTs) with an established peptide cleavage assay to yield quantitative Multiplex Substrate Profiling by Mass Spectrometry (qMSP-MS). This assay was validated with papain, a well-characterized cysteine peptidase, to generate cleavage efficiency values for hydrolysis of 275 unique peptide bonds in parallel. To demonstrate the breath of this assay, we show that qMSP-MS can uncover the substrate specificity of minimally characterized intramembrane rhomboid peptidases, as well as define hundreds of proteolytic activities in complex biological samples, including secretions from lung cancer cell lines. Importantly, our qMSP-MS library uses synthetic peptides whose termini are unmodified, allowing us to characterize not only endo- but also exo-peptidase activity. Each cleaved peptide sequence can be ranked by turnover rate, and the amino acid sequence of the best substrates can be used for designing fluorescent reporter substrates. Discovery of peptide substrates that are selectively cleaved by peptidases which are active at the site of disease highlights the potential for qMSP-MS to guide the development of peptidase-activating drugs for cancer and infectious disease.

19 June 2025 in Cancer Discovery
Verified
Journal Article
Closed access
SGShellaina J.V. Gordon
Shellaina J.V. Gordon
FPFlorian Perner
Florian Perner
LMLaura MacPherson
Laura MacPherson
KFKatie A. Fennell
Katie A. Fennell
DWDaniela Vanessa Wenge
Daniela Vanessa Wenge
MDMark A. Dawson
Mark A. Dawson
Targeting MYST acetyltransferases is an exciting therapeutic opportunity in acute myeloid leukemia (AML). In this study, we define the individual and combined contribution of KAT6A, KAT6B, and KAT7 in a range of AML models, showing that although KAT6A/B inhibition is efficacious in some preclinical models, simultaneous targeting of KAT7, with the novel inhibitor PF-9363, markedly increases efficacy. KAT7 interacts with menin and the mixed lineage leukemia (MLL) complex and is colocalized at chromatin to coregulate oncogenic transcriptional programs. Focusing on MLL fusion oncoprotein (MLL-FP) AML, we show that inhibition of KAT6/KAT7 provides an orthogonal route to targeting menin to disable the transcriptional activity of the MLL-FP. Combined inhibition rapidly evicts the MLL-FP from chromatin, potently represses oncogenic transcription, and overcomes primary resistance to menin inhibitors. Notably, KAT7 remains an important targetable dependency in acquired genetic/nongenetic resistance to menin inhibition, providing the molecular rationale for rapid clinical translation of combination therapy, particularly in MLL-FP AML. Significance: This study provides the molecular rationale for combined targeting of KAT6/7 and menin in MLL leukemia. It reveals that combination therapy results in a rapid and profound repression of the MLL transcriptional program leading to marked differentiation and loss of leukemia-initiating capacity, setting the platform for clinical translation.

29 May 2018 in Cell Discovery
Verified
Journal Article
Open access
PDF file
HWHuawei Wang
Huawei Wang
JLJohn Lapek
John Lapek
KFKen Fujimura
Ken Fujimura
JSJan Strnadel
Jan Strnadel
BLBei Liu
Bei Liu
RKRichard L. Klemke
Richard L. Klemke
PEAK1 is a newly described tyrosine kinase and scaffold protein that transmits integrin-mediated extracellular matrix (ECM) signals to facilitate cell movement and growth. While aberrant expression of PEAK1 has been linked to cancer progression, its normal physiological role in vertebrate biology is not known. Here we provide evidence that PEAK1 plays a central role in orchestrating new vessel formation in vertebrates. Deletion of the PEAK1 gene in zebrafish, mice, and human endothelial cells (ECs) induced severe defects in new blood vessel formation due to deficiencies in EC proliferation, survival, and migration. Gene transcriptional and proteomic analyses of PEAK1-deficient ECs revealed a significant loss of vascular endothelial growth factor receptor 2 (VEGFR2) mRNA and protein expression, as well as downstream signaling to its effectors, ERK, Akt, and Src kinase. PEAK1 regulates VEGFR2 expression by binding to and increasing the protein stability of the transcription factor GATA-binding protein 2 (GATA2), which controls VEGFR2 transcription. Importantly, PEAK1-GATA2-dependent VEGFR2 expression is mediated by EC adhesion to the ECM and is required for breast cancer-induced new vessel formation in mice. Also, elevated expression of PEAK1 and VEGFR2 mRNA are highly correlated in many human cancers including breast cancer. Together, our findings reveal a novel PEAK1-GATA2-VEGFR2 signaling axis that integrates cell adhesion and growth factor cues from the extracellular environment necessary for new vessel formation during vertebrate development and cancer.

20 September 2017 in ACS Nano
Verified
Journal Article
Closed access
JLJr. John D. Lapek
Jr. John D. Lapek
RFRonnie Fang
Ronnie Fang
XWXiaoli Wei
Xiaoli Wei
PLPengyang Li
Pengyang Li
BWBo Wang
Bo Wang
DGDavid J. Gonzalez
David J. Gonzalez

6 October 2025
Verified
Other
Open access
SGShellaina J.V. Gordon
Shellaina J.V. Gordon
FPFlorian Perner
Florian Perner
LMLaura MacPherson
Laura MacPherson
KFKatie A. Fennell
Katie A. Fennell
DWDaniela Vanessa Wenge
Daniela Vanessa Wenge
MDMark A. Dawson
Mark A. Dawson
Supplementary tables updated with KAT7 interactome.